Literature DB >> 12534403

Early events in proton pump inhibitor-associated exacerbation of corpus gastritis.

D Y Graham1, A R Opekun, Y Yamaoka, M S Osato, H M T el-Zimaity.   

Abstract

BACKGROUND: Antisecretory therapy may exacerbate Helicobacter pylori corpus gastritis. The rate and mechanism(s) remain unknown. AIM: To investigate the early events in proton pump inhibitor therapy on antral and corpus H. pylori gastritis.
METHODS: Nine H. pylori-infected volunteers underwent gastric biopsy with jumbo forceps for culture and histology. Histology was scored in the range 0-5 using a visual analogue scale. The depth of inflammation in gastric pits was scored in the range 1-3 (superficial or less than one-third, one-third to two-thirds and greater than two-thirds of the gastric pit, respectively). Tissue interleukin-1 beta and interleukin-8 levels were measured by enzyme-linked immunoabsorbent assay. Omeprazole, 20 mg b.d., was given for 6.5 days and biopsies were repeated on day 7.
RESULTS: Proton pump inhibitor therapy resulted in a fall in H. pylori density in the antrum and corpus. Inflammation and tissue levels of interleukin-8 and interleukin-1 beta decreased in the antrum and increased in the corpus mucosa. There was a significant increase in the depth of inflammation to include the proliferative zone in the corpus.
CONCLUSIONS: Within 1 week of starting proton pump inhibitor therapy, there was a marked extension of corpus inflammation into the gastric pit and an increase in corpus mucosal interleukin-1 beta and interleukin-8 levels. H. pylori eradication should be considered for all patients receiving long-term antisecretory therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534403     DOI: 10.1046/j.1365-2036.2003.01400.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

1.  Managing dyspepsia in a primary care setting.

Authors:  A Kenneth Musana; Steven H Yale; Kevin A Lang
Journal:  Clin Med Res       Date:  2006-12

2.  Helicobacter pylori outer membrane proteins and gastroduodenal disease.

Authors:  Y Yamaoka; O Ojo; S Fujimoto; S Odenbreit; R Haas; O Gutierrez; H M T El-Zimaity; R Reddy; A Arnqvist; D Y Graham
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

3.  Motor fluctuations and Helicobacter pylori in Parkinson's disease.

Authors:  Karl-Erik Rahne; Carl Tagesson; Dag Nyholm
Journal:  J Neurol       Date:  2013-09-04       Impact factor: 4.849

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Atrophic gastritis in young children and adolescents.

Authors:  O Ricuarte; O Gutierrez; H Cardona; J G Kim; D Y Graham; H M T El-Zimaity
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 6.  Diagnosis: gastric intestinal metaplasia - what to do next?

Authors:  David Y Graham; Massimo Rugge; Robert M Genta
Journal:  Curr Opin Gastroenterol       Date:  2019-11       Impact factor: 3.287

Review 7.  NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.

Authors:  Francis K L Chan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States.

Authors:  Hashem B El-Serag; John Y Kao; Fasiha Kanwal; Mark Gilger; Frank LoVecchio; Steven F Moss; Sheila E Crowe; Adam Elfant; Thomas Haas; Ronald J Hapke; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-17       Impact factor: 11.382

9.  Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes.

Authors:  Soumana C Nasser; Mahmoud Slim; Jeanette G Nassif; Selim M Nasser
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

10.  Helicobacter pylori Eradication Therapy in Nonulcer Dyspepsia is Beneficial.

Authors:  Mohammed Q Khan
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.